Can DIO2 rs225014 alter local thyroid hormone signaling even when TSH and free T4 are normal?

The DIO2 rs225014 (Thr92Ala) polymorphism represents a critical genetic determinant of localized thyroid hormone bioactivity that escapes detection by standard systemic thyroid panels.

Intracellular mechanisms

• Enzyme mislocalization and ER stress: The Thr92Ala variant disrupts type 2 deiodinase (D2) proteostasis, causing the enzyme to accumulate abnormally in the trans-Golgi network and triggering endoplasmic reticulum (ER) stress.
• Impaired T4-to-T3 conversion: This intracellular trafficking defect reduces the pool of functional D2 enzyme in the correct cellular compartment, resulting in a 20% to 40% reduction in effective deiodination and diminished local T3 generation.

Tissue-specific signaling and clinical evidence

• Blunted nuclear signaling: Because tissues such as the brain and skeletal muscle rely primarily on intracellular D2-mediated conversion, reduced local T3 limits thyroid receptor binding and blunts downstream transcription, leading to localized, tissue-specific hypothyroidism.
• Independence from systemic markers: This cellular impairment occurs entirely independently of systemic thyroid function. Standard laboratory assays showing normal thyroid-stimulating hormone (TSH) and free T4 (FT4) levels fail to reflect these localized deficits, a phenomenon particularly observed in thyroid-deficient patients on levothyroxine monotherapy who carry the variant.

Bottom line

• The DIO2 rs225014 polymorphism impairs intracellular deiodinase trafficking and proteostasis, reducing local T4-to-T3 conversion and blunting tissue-specific thyroid signaling even when circulating serum TSH and free T4 levels remain entirely normal.